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Abstract 
Objective: Offering a financial incentive (‘Money for Medication’) is effective in improving adherence to treatment 
with depot antipsychotic medications. We investigated the cost-effectiveness in terms of medical costs and judicial 
expenses of using financial incentives to improve adherence. The effects of financial incentives on depot medication 
adherence were evaluated in a randomised controlled trial. Patients in the intervention group received €30 a month 
over 12 months if antipsychotic depot medication was accepted. The control group received mental health care as 
usual. For 133 patients outcomes were calculated based on self-reported service use and delinquent behaviour and 
expressed as standard unit costs to value resource use.
Results: The financial incentive resulted in higher average costs related to mental health care (€449.6 versus €355.7). 
and lower medical costs related to other healthcare services (€52.0 versus €78.4). Relevant differences in social costs 
related to delinquent behaviour were not found. Although wide confidence intervals indicate uncertainty, incremen-
tal cost-effectiveness ratio’s (ICER) indicate that it costs €2080 for achieving a 20% increase in adherence or €3332 for 
achieving over 80% adherence. In sum, offering money as financial incentive for increasing compliance did not lead 
to an overall cost reduction as compared to care as usual.
Trial registration NTR2350, 01 June 2010
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Introduction
Adherence to treatment with antipsychotic depot medi-
cation is associated with remission from symptoms and 
improved social outcomes [1]. Yet 25% to 50% of people 
with schizophrenia are non-adherent to their medica-
tion regimen due to a lack of illness insight or side effects 
[2]. Results of randomized controlled trials suggest that 
offering a financial incentive (‘Money for Medication’) is 
effective in improving adherence [3, 4]. However, direct 
costs increase both because a modest financial incentive 
is offered over an extended period and because logisti-
cal arrangements to distribute money in a community 
mental health context need to be addressed. On the other 
hand, adherence to antipsychotic medication may be 
associated with lower risk of psychiatric hospital admis-
sions and may decrease other health and social care costs. 
In addition, a decrease of psychotic symptoms may con-
tribute to patients’ quality of life and better social adjust-
ment, which could lower societal costs. However, data on 
cost-effectiveness of medication adherence-enhancing 
interventions are rare [5]. And although first economic 
outcomes for offering financial incentives point in the 
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right direction, effect estimates show wide confidence 
intervals [6].
Therefore, we investigated the medical and judicial 
costs after offering financial incentives to achieve bet-
ter adherence. In a trial studying the effects of finan-
cial incentives on depot-adherence and psychosocial 
outcomes [4], we found a significant improvement in 
adherence rates, although no effects were found on psy-
chosocial outcomes, including quality of life. Here our 
focus is on patients’ health care consumption and costs 
that incurred because of illegal activities. We did not 
study cost-effectiveness in terms of quality adjusted life 
years (QALY’s), since the intervention did not affect qual-
ity of life, which was a secondary outcome. We investi-
gated the differences in direct medical costs (related to 
psychiatric treatment), medical costs related to other 
healthcare services, and judicial costs, between the 
intervention and control group, and how these costs are 
related to better antipsychotic medication adherence. To 
estimate expenditures from a societal perspective, costs 
were calculated by multiplying resource use with official 
charge standards.
Main text
Methods
Medical and judicial costs
The effect of financial incentives on depot medication 
adherence was evaluated in a randomised controlled 
trial: 169 patients with a psychotic disorder were ran-
domised to intervention or control groups, stratified by 
treatment site, sex, comorbid substance-use disorder, 
and medication compliance [7]. Patients in the control 
group received mental and primary health care as usual. 
Patients in the intervention group received the same 
treatment plus €30 a month over 12-months if antipsy-
chotic depot medication was fully taken. For 35 patients 
no data were available regarding costs, yet baseline and 
follow-up proportions of patients using services cor-
respond. Therefore we calculated for 133 (79%) patients 
direct medical costs and costs related to other healthcare 
services based on standard unit costs to value resource 
use at baseline and after 12-months follow-up. Data 
were collected from the patients’ file, from the depot 
acceptance registration forms, and from questionnaires 
that assessed use of healthcare services and delinquent 
behaviour.
Costs related to service use
The Treatment Inventory Cost in psychiatric patients 
(TiC-P) [8] is a frequently used generic self-report out-
come measure in adult patients with a psychiatric diag-
nosis. Validity of self-report service use is acceptable [9]. 
The full version of the questionnaire includes health care 
use, medication, and absence of work or other activities. 
The items concern the volume of medical consumption 
and productivity loss over the past 4  weeks. We used 
the part of the TiC-P that comprises 14 structured ques-
tions on contacts within the mental health care sector 
and contacts with other health services, ranging from 
general practitioner to homecare. Following the guide-
lines of the Dutch manual of costing studies in health 
care [10], total costs were calculated as the sum of the 
product of reported frequencies and the reference price 
regarding the type of healthcare use. Mental health care 
costs were considered as part of treatment related direct 
costs, whereas other medical consumption was labelled 
as general medical costs related to other healthcare ser-
vices. Table 1 summarizes the medical cost items, refer-
ence prices, and the number of contacts or hospital days 
at baseline.
Costs related to delinquency
The Self-Reported Delinquency questionnaire (SRD) pro-
vides an account of a wide range of illegal acts and has 
been widely used, although item difficulty varies across 
subgroups [11]. We copied the questionnaire from the 
Dutch version of the INternational CAnnabis Need of 
Treatment study (INCANT) [12–14]. The SRD question-
naire examines the frequency of minor delinquent acts 
(e.g. vandalism) and criminal acts (e.g. armed robbery). 
Patients were asked to report on the number of times the 
specified delinquent behaviour was performed in the last 
4 weeks. Contrary to health care contacts, types of delin-
quency have no generally accepted reference costs. How-
ever, Goorden et al. [15] estimated costs based on annual 
judicial expenses and the number of registered crimes 
and violations broken down into categories comparable 
to categories used in the SRD. We followed this approach 
to differentiate costs linked to the SRD items; the unit 
prices were multiplied by the reported frequency of the 
specific delinquent behaviour and summed to obtain an 
estimate of the total delinquency costs. Additional file 1: 
Appendix S1 shows the list of types of delinquent behav-
iour, unit prices, and the reported frequencies at baseline.
Statistical analysis
Medical costs are typically characterized by an asym-
metry of the distribution because some patients have 
minimal costs or specific standard cost amounts and 
other patients may have disproportionately high costs. 
Generalized linear models using a log-gamma distri-
bution, have been suggested to account for this kind of 
highly skewed data [16]. We used the GenLin procedure 
in SPSS version 21 to model differences in direct mental 
healthcare costs, medical costs related to other health-
care services, and judicial costs between the intervention 
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and control groups. Means and standard deviations are 
reported to describe the costs per category of service 
use and type of delinquency and to illustrate the asym-
metry of cost data. Both medical and judicial total costs 
are dominated by items that are infrequent but have rela-
tively high unit prices. Table 1 shows that an important 
part of the average medical costs per patient comes from 
only a few patients who were hospitalised. In Additional 
file 1: Appendix S1 the social costs of robbery stand out. 
Therefore, we looked at differences in the sum of costs 
both with and without including hospitalisation costs. 
Multivariable analysis focussed on the main effect of 
the intervention on medical and judicial costs, adjusting 
for stratification variables (i.e. gender, baseline compli-
ance and substance use). Statistical significance of the 
regression coefficient was tested using the Wald-test 
and a conventional .05 significance level. In addition, 
an incremental cost-effectiveness ratio (ICER) was cal-
culated by dividing the incremental total costs per year 
by the incremental effects and creating a bootstrapped 
95% confidence interval based on 1000 replications. 
First, we considered the incremental costs of achieving 
a 20% increase in adherence following Henderson et  al. 
[6]. Secondly, we calculated the incremental costs of 
achieving ‘good’ adherence i.e., taking at least 80% of the 
prescribed depot medications over the 12-month inter-
vention period, since this cut-off has been recommended 
by expert consensus guidelines [17].
Results
At baseline, between groups differences were negligible. 
For a detailed account of baseline patient characteristics 
see Noordraven et  al. [4]. An adherence difference of 
14.9% (95% CI 8.9%, 20.9%) was found for the medica-
tion possession ratio, and the difference in the proportion 
of patients achieving good (≥ 80%) adherence levels was 
33.1% (95% CI 20.2% to 45.4%) in favour of in the inter-
vention group [4]. This result is reflected in higher costs 
related to psychiatric treatment at 12-months follow-up 
in the intervention condition compared to care as usual 
(€1062.9 vs. €788.8). However, regression analysis con-
trolling for stratification variables indicated a statistically 
Table 1 Service unit costs and average costs per patient at baseline (previous 4 weeks)
a  Other than a general hospital, an academic hospital, or a rehabilitation center
Unit costs € n (%) patients 
using service
Average costs 
per patient 
(SD)
Medical costs related to psychiatric treatment
 Contact with a caregiver from a regional institute for outpatient mental healthcare 113 150 (89%) 408.3 (509.4)
 Contact with a psychiatrist, psychologist or psychotherapist at a private (group) practice 95 16 (10%) 14.1 (66.1)
 Contact with a psychiatrist, psychologist or psychotherapist (i.e. outpatient visit in hospital) 95 11 (7%) 12.4 (69.2)
 Contact with a clinic for alcohol and drugs 31 2 (1%) 5.5 (66.9)
 Participation in a self-help group 58 4 (2%) 3.1 (22.2)
 Day- or part-time psychiatric hospital treatment 278 5 (3%) 28.5 (267.9)
 Psychiatric hospitalisation 446 6 (4%) 393.2 (2832.8)
Subtotal average sum
Excluding hospitalisation
169 (100%) 901.4 (2982.5)
508.2 (682.8)
Medical costs related to other healthcare services
 Contact with a general practitioner 33 44 (26%) 13.1 (25.8)
 Contact with a company doctor 33 2 (1%) 0.4 (3.6)
 Contact with a medical specialist (i.e. outpatient visit in hospital) 92 17 (10%) 21.8 (102.0)
 Contact with a physiotherapist 33 3 (2%) 1.2 (10.7)
 Contact with a social worker 65 33 (20%) 37.7 (125.2)
 Home care 20 17 (10%) 13.4 (47.5)
 Contact with an alternative healer 51 2 (1%) 1.8 (17.5)
 Day- or part-time treatment 278 – –
 Other  hospitala 170 – –
 Hospitalisation 446 3 (2%) 39.6 (310.9)
Subtotal average sum
Excluding hospitalisation
169 (100%) 91.2 (337.5)
54.7 (127.6)
Total medical costs 992.6 (3008.8)
Total costs, excluding hospitalisation 559.8 (702.1)
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insignificant difference in total medical costs between 
the intervention and control group (€1592.5 vs. €1272.8; 
B = .517, SE = .282, p = .067). Table 2 shows that this dif-
ference is due to costs of psychiatric hospitalisation, not 
as much to more frequent regular contacts with out-
patient mental health care excluding hospitalisations 
(€484.4 vs. €432.5; B = .251, SE = .206, p = .222).
In the intervention group average medical costs related 
to other healthcare services were somewhat higher com-
pared to the control group (€529.6 versus €484.0), but 
lower after excluding hospitalisation (€52.0 versus €78.4). 
Fewer patients in the Money-for-Medication program 
visited their GP, a medical specialist, or social worker. 
This effect was in the expected direction but small (statis-
tical models did not adequately converge).
Additional file  1: Appendix S1 illustrates that delin-
quent behaviour is not very common among patients 
with psychotic disorder. Minor offences are most 
frequently reported but less than 6% of patients are 
involved in shoplifting incidents or buying and selling 
stolen goods. At 12-months follow-up very few patients 
reported delinquent behaviour (Table 3) and only small 
differences in related social costs were found com-
paring the intervention group and the control group 
(€248.4 vs. €229.3; B = .607, SE = .420, p = .149). Dur-
ing the 18-month follow up period, results remained 
comparable both for the healthcare (Additional file  2: 
Appendix S2) and judicial related costs (Additional 
file 3: Appendix S3).
On average, the maximum of 30 euro extra cost item 
as financial incentive per patient per month constitutes 
about 3% of average total mental healthcare costs (€1062) 
and less than 7% of outpatient medical costs (€449). 
Extrapolating costs, excluding hospitalisation, in the 
previous 4  weeks at 12  months follow-up to total costs 
per patient per year, averaged to €9273 (SD 13512) in the 
Money-for-Medication group and to €7900 (SD 19089) 
in the care-as-usual group. Incremental total costs were 
€2080 (95% CI − 37972 to 34811) for achieving a 20% 
increase in adherence and €3332 (95% CI − 22675 to 
28128) for taking at least 80% of the prescribed depot 
medications over the 12-month intervention period.
Table 2 Service costs at 12 months follow-up (previous 4 weeks)
Intervention group
n (%) patients
Average costs
(SD)
Control group
n (%) patients
Average costs
(SD)
Medical costs related to psychiatric treatment
 Contact with a caregiver from a regional institute for outpatient mental 
healthcare
58 (91%) 410.1 (532.5) 60 (87%) 269.9 (361.1)
 Contact with a psychiatrist, psychologist or psychotherapist at a private 
(group) practice
5 (8%) 12.1 (55.3) 17 (25%) 33.5 (78.3)
 Contact with a psychiatrist, psychologist or psychotherapist (i.e. outpa-
tient visit in hospital)
2 (3%) 2.9 (16.7) 3 (4%) 4.1 (19.5)
 Contact with a clinic for alcohol and drugs – – 1 (1%) 0.9 (7.5)
 Participation in a self-help group 3 (5%) 17.2 (93.4) 1 (1%) 1.7 (13.9)
 Day- or part-time psychiatric hospital treatment – – 1 (1%) 4.0 (33.5)
 Psychiatric hospitalisation 3 (5%) 613.3 (2788.7) 3 (4%) 433.1 (2284.4)
 Intervention costs financial incentives 64 (100%) 28.6 (3.2) 0 (0%) 0 (0.0)
Subtotal average sum
Excluding hospitalisation
1062.9 (3031.5)
449.6 (530.4)
788.8 (2379.3)
355.7 (463.9
Medical costs related to other healthcare services
 Contact with a general practitioner 16 (25%) 8.8 (15.8) 22 (32%) 15.5 (28.2)
 Contact with a company doctor 1 (1%) 0.5 (4.1) 1 (1%) 0.5 (4.0)
 Contact with a medical specialist (i.e. outpatient visit in hospital) 3 (5%) 4.3 (19.6) 9 (13%) 14.7 (40.6)
 Contact with a physiotherapist 2 (3%) 4.6 (33.2) 2 (3%) 3.3 (21.3)
 Contact with a social worker 9 (14%) 20.6 (64.8) 12 (17%) 50.6 (241.9)
 Home care 5 (8%) 16.6 (60.9) 5 (7%) 10.7 (43.2)
 Contact with an alternative healer – – – –
 Day- or part-time treatment – – 1 (1%) 32.2 (267.7)
 Hospitalisation 4 (6%) 494.8 (2246.4) 3 (4%) 407.2 (2263.5)
Subtotal average sum
Excluding hospitalisation
529.6 (2241.7)
52.0 (117.8)
484.0 (2266.6)
78.4 (278.4)
Total costs
Excluding hospitalization
64 (100%) 1592.5 (3700.7)
484.4 (538.9)
69 (100%) 1272.8 (3223.7)
432.5 (536.1)
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Discussion
Providing a financial incentive to improve adherence to 
depot medication in psychotic patients resulted in higher 
average costs directly related to mental health care and 
lower costs related to other health care services. Relevant 
differences in social costs related to delinquent behaviour 
were not found.
An increase in medication compliance was reflected 
in mental healthcare costs, which were higher in the 
Money-for-Medication group compared to the control 
group. In contrast, medical costs related to other health 
care services were somewhat lower in the interven-
tion group. Effects in terms of medical costs were in the 
expected direction but differences between the inter-
vention and control group were not statistically signifi-
cant. Social costs related to delinquency concerned few 
patients and only minor and non-significant differences 
were found comparing the intervention and control 
group.
Intervention costs are low considering a maximum 
financial incentive of 360 euro per patient per year. 
Currently no threshold values are available for the 
ICER-values in the range of €2000 for achieving a 20% 
increase in adherence, and just over €3000 for ‘good’ 
(80% or higher) medication adherence. Interestingly, 
these figures are in line with the results of Henderson 
et  al. [6], which estimated these costs in the range of 
€1144 and €3400 respectively. The ‘Money for Medica-
tion’ study supports these results and is the first trial 
within the Netherlands and the second and largest trial 
worldwide, which makes it and an important replica-
tion study. In sum, this suggests that we may be able 
to increase compliance with depot medication to an 
appropriate level when we are willing to invest extra. 
However, incremental cost-effectiveness ratio’s (ICER) 
showed wide confidence intervals indicating a high 
level of uncertainty.
Conclusions
Financial incentives are effective in improving treat-
ment adherence in patients with psychotic disor-
der. However, offering money as financial incentive 
for increasing compliance did not lead to an overall 
cost reduction as compared to care as usual. Perhaps 
that financial benefits of M4M in terms of reductions 
in medical costs might become manifest only after a 
longer period of time. Therefore, future studies using 
longer intervention and follow-up periods are needed 
to investigate cost-effectiveness also with respect to 
quality of life.
Table 3 Delinquent behaviour costs at 12 months follow-up (previous 4 weeks)
Intervention
Group
n (%) patients
Average costs
(SD)
Control Group
n (%) patients
Average costs
(SD)
Damaged a vehicle – – – –
Damaged public objects – – – –
Besmirched something – – – –
Arson – – – –
Changed price labels in a shop – – – –
Shoplifting 1 (1%) 28.8 (237.7) – –
Stole something at work – – – –
Stole a bicycle or scooter – – 1 (1%) 148.5 (1206.3)
Stole something of a car – – – –
Buying stolen goods 3 (4%) 75.9 (460.0) – –
Soled something stolen 1 (1%) 24.9 (205.4) 1 (1%) 25.7 (208.5)
Stole something out of a car 1 (1%) 28.8 (237.7) – –
Cartheft – – –
Burglary – – – –
Pickpocketing 1 (1%) 28.8 (237.7) – –
Robbery – – – –
Agressive behavior – – – –
Violent behavior – – 1 (1%) 55.1 (447.8)
Armed violence 1 (1%) 62.3 (513.4) – –
Total 64 (100%) 248.4 (856.2) 69 (100%) 229.3 (1477.4)
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Limitations
Medical and judicial cost items were patient reported 
over a 4  weeks’ time span which may reduce memory 
bias, but may not adequately reflect variability in the 
level of health service use or delinquent behaviour in 
our 12-month study period. Also, the national reference 
costs per health care contact or type of delinquency were 
crude estimates of the true mental healthcare cost, medi-
cal costs related to other health care services, and social 
costs.
The Self-Reported Delinquency questionnaire origi-
nally was aimed at adolescents and may be less suited for 
mapping delinquent behaviour in psychiatric patients, 
which may explain the low frequency of reported delin-
quent behaviour. In addition, we maybe overestimated 
the amount of criminal activities within a non-forensic 
patient setting; patients with chronic psychiatric diseases 
are not necessarily involved in criminal activities.
During this study, frequency of other social parameters 
(e.g. participation in volunteer work) were not assessed 
and the invested time per patient to arrange appoint-
ments for proving depot medication was not monitored, 
so it remains unclear whether implementing M4M did 
actually save or cost extra time. Furthermore, our study 
was underpowered for the analysis of highly skewed cost 
data, resulting in wide bootstrapped confidence intervals 
for incremental cost-effectiveness ratios.
Additional files
Additional file 1: Appendix S1. Judicial unit prices and baseline costs. 
The file includes a table with the judicial unit prices and costs at baseline 
for all patients.
Additional file 2: Appendix S2. Service costs 18 months. The file 
includes a table with the follow-up data for the service costs at 18 months.
Additional file 3: Appendix S3. Judicial costs 18 months. The file 
includes a table with the follow-up data for the service costs at 18 months.
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